Engensis (VM202)

BIOLOGICAL3 trials

Sponsors

Helixmith Co., Ltd.

Conditions

CMTDiabetic Neuropathy, PainfulFoot Ulcer, DiabeticPainful Diabetic Neuropathy

Phase 1

The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)

CompletedNCT05361031

Helixmith Co., Ltd.CMT

Start: 2020-09-21End: 2022-02-22Updated: 2025-10-06

Phase 3

Phase 3 Gene Therapy for Painful Diabetic Neuropathy

CompletedNCT02427464

Helixmith Co., Ltd.Diabetic Neuropathy, Painful, Painful Diabetic Neuropathy

Start: 2016-04-30End: 2019-04-30Updated: 2025-10-09

Safety and Efficacy Study of Engensis (VM202) in the Treatment of Chronic Non-Healing Foot Ulcers

TerminatedNCT02563522

Helixmith Co., Ltd.Foot Ulcer, Diabetic

Start: 2017-06-27End: 2019-09-24Updated: 2025-10-09

Related Papers

An open-label single-arm phase 1/2a study to evaluate the safety and exploratory efficacy of a VM202 in patients with Charcot-Marie-Tooth disease 1A

Orphanet Journal of Rare Diseases2026-03-05